Jeffrey V Leyton

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Diffusion Weighted

Endoplasmic Reticulum

Top Venues

Antibodies (Basel, Switzerland)

Chemical Society reviews

EJNMMI research

Bioconjugate chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Ritabrita Goswami, Aarohi Gupta, Olga Bednova, Gaël Coulombe, Dipika Patel, Vincent M Rotello, Jeffrey V Leyton
Nuclear localization signal-tagged systems: relevant nuclear import principles in the context of current therapeutic design. Chemical Society reviews (2023)
Manar Hammood, Andrew W Craig, Jeffrey V Leyton
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel, Switzerland) 14 (7) (2021)
Jeffrey V Leyton
Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics-The Tale of HER2. Antibodies (Basel, Switzerland) 9 (3) (2020)
Michel Paquette, Serge Phoenix, Christine Lawson, Brigitte Guérin, Roger Lecomte, Lee-Hwa Tai, Éric E Turcotte, Jeffrey V Leyton
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI research 10 (1) (2020)
Michel Paquette, Simon Beaudoin, Mylene-Annie Tremblay, Steve Jean, Angel F Lopez, Roger Lecomte, Brigitte Guérin, M'hamed Bentourkia, Robert Sabbagh, Jeffrey V Leyton
NLS-Cholic Acid Conjugation to IL-5Rα-Specific Antibody Improves Cellular Accumulation and In Vivo Tumor-Targeting Properties in a Bladder Cancer Model. Bioconjugate chemistry 29 (4) (2018)